Medicare's PAMA Problem: Will 2026 Reimbursement Cuts Crush US Diagnostics Innovation?

This episode examines the critical threat facing the U.S. diagnostics industry due to flawed implementation of the Protecting Access to Medicare Act (PAMA). We explore how skewed data collection has led to severe reimbursement cuts, disproportionately impacting smaller, innovative labs. We discuss the 2026 outlook, the looming risk of market consolidation, and how this environment stifles investment in new diagnostic technologies, potentially limiting patient access to care. - What is the Protecting Access to Medicare Act (PAMA) and why is it a threat to US labs? - How do reimbursement cuts disproportionately harm smaller, innovative diagnostics companies? - What is the significance of the 2026 deadline for Medicare lab payments? - Could ongoing payment pressure lead to mass consolidation in the diagnostics market? - How does this environment impact investment in new testing platforms? - What is the RESULTS Act and could it be a permanent solution? - What are the long-term risks to patient access to advanced diagnostics in the US? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI. We help you develop efficient regulatory strategies, leveraging your existing approvals to identify the best new markets for expansion. Our team uses powerful data tools to compile and submit technical dossiers, helping you navigate complex landscapes like the U.S. reimbursement system to bring your innovations to patients faster. For a smarter path to global market access, contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.